A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Patch
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Jun 2018
At a glance
- Drugs Rivastigmine (Primary)
- Indications Dementia
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 06 Jun 2018 Planned initiation date changed from 31 Mar 2018 to 31 Aug 2018.
- 25 Mar 2018 Planned End Date changed from 30 Nov 2018 to 3 Feb 2020.
- 25 Mar 2018 Planned primary completion date changed from 30 Nov 2018 to 3 Feb 2020.